Versor Investments LP Buys 1,502 Shares of Medpace Holdings, Inc. $MEDP

Versor Investments LP grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 150.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,501 shares of the company’s stock after purchasing an additional 1,502 shares during the quarter. Versor Investments LP’s holdings in Medpace were worth $1,286,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Profund Advisors LLC bought a new position in Medpace in the 3rd quarter valued at about $266,000. Fielder Capital Group LLC boosted its holdings in shares of Medpace by 14.0% during the third quarter. Fielder Capital Group LLC now owns 731 shares of the company’s stock worth $376,000 after acquiring an additional 90 shares during the period. Jackson Square Partners LLC grew its position in shares of Medpace by 91.3% in the third quarter. Jackson Square Partners LLC now owns 17,843 shares of the company’s stock valued at $9,174,000 after purchasing an additional 8,517 shares during the last quarter. Renaissance Group LLC increased its stake in shares of Medpace by 8.6% during the third quarter. Renaissance Group LLC now owns 19,926 shares of the company’s stock worth $10,245,000 after purchasing an additional 1,577 shares during the period. Finally, Renasant Bank acquired a new stake in Medpace during the 3rd quarter worth approximately $230,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. This trade represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 302,192 shares of company stock worth $182,019,762 over the last three months. Insiders own 20.30% of the company’s stock.

Medpace Stock Down 2.2%

MEDP opened at $530.35 on Tuesday. The stock has a market capitalization of $14.94 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 1.82 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The company has a 50-day simple moving average of $578.30 and a 200 day simple moving average of $539.57.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the firm earned $3.67 EPS. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Barclays upped their price objective on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Mizuho set a $660.00 price target on shares of Medpace in a research note on Friday, January 9th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Finally, Truist Financial set a $555.00 target price on shares of Medpace in a research report on Monday, October 27th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.